HSPA5 and neoplasm: Targeting GRP78 through small-molecule inhibitors, monoclonal antibodies, and emerging therapies such as CAR T cell therapy shows promising potential to disrupt tumor-promoting pathways, overcome resistance mechanisms, and improve therapeutic outcomes.